Clinicians can use the system to switch between single and double-needle access at any point during the procedure. Credit: Ewa Urban from Pixabay.

Healthcare company Fresenius Kabi has introduced a new single-needle venous access option for the Amicusextracorporeal photopheresis (ECP) system.

In 2019, the Amicus Blue System featuring online ECP was introduced in Europe, enabling venous access exclusively through double-needle.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Fresenius Kabi MedTech president Christian Hauer said: “We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access.

“This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs.”

The company has launched the latest software versions: v6.1 for the Amicus Separator and v2.1 for the Phelix Photoactivation Device.

It also introduced a new single-use disposable kit that can be customised to provide venous access through single or double-needle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The system allows clinicians to seamlessly switch between single and double-needle access during the procedure.

The CE mark for the Amicus ECP system was granted for the approved indication of palliative treatment of the skin manifestations of cutaneous T cell lymphoma that is unresponsive to other treatments.

The ECP system consists of the Amicus Separator, the Phelix Photoactivation Device and Amicus ECP Apheresis Kits.

Furthermore, the separator system is approved in Europe and the US for therapeutic plasma exchange, mononuclear cell collection, red blood cell exchange and platelet collection.

Meanwhile, the Amicus ECP System is not yet approved for use in the US.